Lisata Therapeutics, Inc. (LSTA) Income Statement
LSTA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsLSTA revenue and net income
Where LSTA's revenue goes
2025Each bar shows an amount and its share of revenue. LSTA kept −9,756.5% of revenue as net income.
LSTA profit margins
LSTA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −83.0% | −88.8% | — | −38.6% |
| Gross profit | −97.6% | −92.8% | — | −36.7% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
LSTA quarterly EPS vs estimates
Lisata Therapeutics beat the analyst EPS estimate in 5 of the last 7 quarters. Next report: November 5, 2026.
LSTA income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $170,000 | $1.0M | $0 | $121.4M | $0 | $0 | $0 | $0 | $0 | $35.3M |
| Cost of revenue | $146,000 | $174,000 | $189,000 | $69,000 | $55,000 | $63,000 | $65,000 | $225,000 | $372,000 | $450,266 |
| Gross profit | $24,000 | $1.0M | −$189,000 | $63.8M | −$55,000 | −$63,000 | −$65,000 | −$225,000 | −$372,000 | $4.1M |
| Research & development | $7.9M | $11.3M | $12.7M | $43.5M | $17.6M | $9.3M | $13.5M | $7.6M | $17.1M | $15.1M |
| Sales, general & admin | $10.4M | $12.1M | $13.0M | $14.1M | $11.5M | $9.9M | $9.3M | $9.4M | $11.8M | $12.8M |
| Total operating expenses | $18.2M | $23.4M | $25.7M | $57.6M | $29.1M | $19.1M | $20.1M | $17.0M | $27.6M | $35.5M |
| Operating income | −$18.2M | −$22.4M | −$25.7M | −$57.6M | −$29.1M | −$19.1M | −$20.1M | −$17.0M | −$27.6M | −$31.3M |
| Interest expense | — | — | — | $1.9M | $227,000 | $123,000 | $0 | $5,000 | $377,768 | $1.9M |
| Income before taxes | −$17.5M | −$20.8M | −$23.2M | −$56.7M | −$29.0M | −$19.0M | −$19.4M | −$16.2M | −$27.7M | −$31.3M |
| Income taxes | −$962,000 | −$798,000 | −$2.3M | −$2.5M | −$1.5M | −$10.9M | $749,000 | −$1,000 | −$11.5M | $138,038 |
| Net income | −$16.6M | −$20.0M | −$20.8M | −$54.2M | −$27.5M | −$8.2M | −$20.1M | −$16.2M | $23.0M | −$32.7M |
| EBITDA | −$17.4M | −$20.6M | −$23.0M | −$56.6M | −$28.9M | −$19.1M | −$20.0M | −$16.8M | −$27.2M | −$29.0M |
| EPS (diluted) | −$1.91 | −$2.40 | −$2.58 | −$4.93 | −$7.80 | −$6.75 | −$28.05 | −$24.90 | −$31.89 | −$78.75 |
| Gross margin | 14.1% | 100.0% | — | 52.5% | — | — | — | — | — | 11.8% |
| Operating margin | −10,711.2% | −2,240.9% | — | −47.5% | — | — | — | — | — | −88.8% |
| Net margin | −9,756.5% | −1,998.5% | — | −44.7% | — | — | — | — | — | −92.6% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $100,000 | $0 | $70,000 | $0 | $1.0M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $3,000 | $2,000 | $15,000 | — | $44,000 | $43,000 | $41,000 | $41,000 | $45,000 | $46,000 | $47,000 | $47,000 |
| Gross profit | −$3,000 | −$2,000 | $100,000 | — | $70,000 | −$43,000 | $1.0M | −$41,000 | −$45,000 | −$46,000 | −$47,000 | −$47,000 |
| Research & development | $584,000 | $1.2M | $1.1M | $2.0M | $2.3M | $2.6M | $3.0M | $2.5M | $2.6M | $3.2M | $3.0M | $3.4M |
| Sales, general & admin | $3.4M | $3.7M | $2.0M | $2.5M | $2.7M | $3.2M | $3.0M | $2.8M | $3.0M | $3.4M | $3.1M | $2.6M |
| Total operating expenses | $4.0M | $4.9M | $3.2M | $4.4M | $4.9M | $5.8M | $5.9M | $5.3M | $5.5M | $6.6M | $6.0M | $6.0M |
| Operating income | −$4.0M | −$4.9M | −$3.1M | −$4.4M | −$4.9M | −$5.8M | −$4.9M | −$5.3M | −$5.5M | −$6.6M | −$6.0M | −$6.0M |
| Income before taxes | −$2.9M | −$4.9M | −$3.0M | −$4.2M | −$4.7M | −$5.7M | −$4.6M | −$4.9M | −$5.0M | −$6.2M | −$5.4M | −$5.3M |
| Income taxes | — | −$387,000 | — | — | — | −$962,000 | −$20.0M | — | — | −$798,000 | $3,188 | −$714,000 |
| Net income | −$2.9M | −$4.5M | −$3.0M | −$4.2M | −$4.7M | −$4.7M | −$4.6M | −$4.9M | −$5.0M | −$5.4M | −$5.4M | −$5.3M |
| EBITDA | −$4.0M | −$4.9M | −$2.9M | −$4.2M | −$4.6M | −$5.6M | −$4.6M | −$4.9M | −$5.0M | −$6.2M | −$5.3M | −$5.2M |
| EPS (diluted) | −$0.54 | −$0.33 | −$0.33 | −$0.49 | −$0.54 | −$0.55 | −$0.55 | −$0.59 | −$0.61 | −$0.65 | −$0.66 | −$0.65 |
| Gross margin | — | — | 100.0% | — | 100.0% | — | 100.0% | — | — | — | — | — |
| Operating margin | — | — | −3,079.0% | — | −6,954.3% | — | −494.9% | — | — | — | — | — |
| Net margin | — | — | −2,954.0% | — | −6,655.7% | — | −461.0% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in LSTA's financial statements (latest annual report filed March 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
LSTA financial results
In fiscal year 2025 (ended December 31, 2025), Lisata Therapeutics reported revenue of $0.2 million, down 83.0% from the year before. It had a net loss of $16.6 million, a net profit margin of −9,756.5%. Diluted earnings per share came to −$1.91.
See the LSTA stock overview for the latest quote and news, or the LSTA chart for price history and technical indicators.
LSTA income statement FAQ
What is Lisata Therapeutics's annual revenue?
Lisata Therapeutics reported total revenue of $0.2 million for fiscal year 2025, which ended on December 31, 2025. That was down 83.0% from $1.0 million the previous year.
Is Lisata Therapeutics profitable?
No. Lisata Therapeutics reported a net loss of $16.6 million in fiscal 2025, a net profit margin of −9,756.5%; its operating margin was −10,711.2%.
What is Lisata Therapeutics's gross margin?
Lisata Therapeutics's gross margin was 14.1% in fiscal 2025: for every $100 of revenue, Lisata Therapeutics kept $14 after the direct cost of its products and services.
How much does Lisata Therapeutics spend on research and development?
Lisata Therapeutics spent $7.9 million on research and development in fiscal 2025, 4,675.9% of revenue.
What are Lisata Therapeutics's earnings per share?
Lisata Therapeutics earned $-1.91 per diluted share in fiscal 2025, compared with $-2.40 a year earlier.
When will Lisata Therapeutics report its next earnings?
Lisata Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does Lisata Therapeutics's fiscal year end?
Lisata Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 12, 2026.